Document:

EX-10.1

 Exhibit 10.1 

THIRD AMENDMENT TO PURCHASE AND SALE AGREEMENT 

This Third Amendment to Purchase and Sale Agreement (this “Amendment”), dated August 17, 2020, by and among Alkermes
Pharma Ireland Limited, a private company limited by shares and incorporated in Ireland (“APIL”), Daravita Limited, a private company limited by shares and incorporated in Ireland (“Daravita”), Alkermes US Holdings,
Inc. (as successor in interest to Eagle Holdings USA, Inc.), a Delaware corporation (together with APIL, “Sellers”), and Baudax Bio, Inc. (as successor in interest to Recro Pharma, Inc. (“Recro Pharma”) and
Recro Gainesville LLC (successor to Recro Pharma LLC)), a Pennsylvania corporation (“Baudax”), amends that certain Purchase and Sale Agreement, dated as of March 7, 2015 and amended on each of December 8, 2016 and
December 20, 2018, by and among Sellers, Daravita, Recro Gainesville and Recro Pharma (as amended, the “Agreement”). 

RECITALS 
 WHEREAS, Recro Pharma
and Baudax are parties to that certain Separation Agreement, dated as of November 20, 2019, pursuant to which Recro Pharma assigned, or caused its subsidiaries to assign, certain of its assets, rights and obligations to Baudax, including the
Agreement; and 
 WHEREAS, pursuant to Section 11.9 of the Agreement, Daravita, Sellers and Baudax now desire to amend the Agreement as
set forth herein. 
 NOW, THEREFORE, in consideration of the mutual promises hereinafter set forth, and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows: 
 ARTICLE I

 DEFINITIONS 
 1.1
Defined Terms. Capitalized terms used but not defined in this Amendment shall have the meanings ascribed to them in the Agreement. 

ARTICLE II 
 AMENDMENT 

2.1 Exhibit E. Section 2.1(a) of Exhibit E to the Agreement is hereby deleted in its entirety and replaced
with the following: 
 “(a) Development Milestone Earn-Out Consideration.

 (i) The following amounts (“Development Milestone Earn-Out
Consideration”) shall be payable in accordance with Section 2.8 of the Agreement and this Exhibit E upon achievement of the following events (“Development Milestones”) by Purchaser and its
Affiliates, licensees and sublicensees, and shall be non-refundable and non-creditable and not subject to deduction or set-off:

 (A) Within thirty (30) calendar days following December 20, 2018,
Purchaser shall pay to APIL Five Million U.S. Dollars (US$5,000,000.00) and within thirty (30) calendar days following March 24, 2019, Purchaser shall pay to APIL Five Million U.S. Dollars (US$5,000,000.00); and (B) the
following amounts: 
  

					
	 Development Milestone
	  	Amount of Development
Milestone Earn-Out
Consideration (U.S.
Dollars)	 
	 Approval of an NDA for the first Earn-Out Product (the
“First Approval”)
	  	$	5,000,000.00	 
	 First anniversary of the First Approval
	  	$	6,429,000.00	 
	 Second anniversary of the First Approval
	  	$	6,429,000.00	 
	 Third anniversary of the First Approval
	  	$	6,429,000.00	 
	 Fourth anniversary of the First Approval
	  	$	6,429,000.00	 
	 Fifth anniversary of the First Approval
	  	$	6,429,000.00	 
	 Sixth anniversary of the First Approval
	  	$	6,429,000.00	 
	 Seventh anniversary of the First Approval
	  	$	6,429,000.00	 

 (ii) Purchaser shall notify and pay to APIL (A) with respect to the Development Milestone
Earn-Out Consideration payable upon the First Approval, (x) Two Million Five Hundred Thousand U.S. Dollars (US$2,500,000.00) of such payment amount on or prior to August 18, 2020, (y) One Million
Sixty Thousand U.S. Dollars (US$1,060,000.00) of such payment amount on or prior to December 20, 2020 and (z) One Million Four Hundred Forty Thousand U.S. Dollars (US$1,440,000.00) of such payment amount on or prior to June 20, 2021
and (B) each Development Milestone Earn-Out Consideration payment other than the First Approval payment within thirty (30) calendar days after the occurrence of the corresponding Development
Milestone. Each payment made pursuant to Section 2.1(a) of this Exhibit E shall be made by wire transfer of immediately available funds to such account or accounts as are designated in writing by APIL.” 

ARTICLE III 
 3.1
Fee. In consideration of the amendment of the timing of the Development Milestone Earn-Out Consideration payable upon the First Approval, as set forth in Article II of this Amendment, contemporaneous with the signing of this Amendment Baudax
has paid to APIL a one-time, non-refundable and non-creditable (and not subject to deduction or set-off) fee in the amount of Two Hundred Eighty Five Thousand U.S. Dollars (US$285,000). 

  
 -2- 

 ARTICLE IV  

GENERAL 
 4.1 Effect of
Amendment. The Agreement is hereby amended as set forth in this Amendment. Except as specifically provided for in this Amendment, all of the terms and conditions of the Agreement shall remain in full force and effect. Each reference in the
Agreement to “hereof,” “hereunder” and “this Agreement” shall, from and after the date of this Amendment, refer to the Agreement, as amended by this Amendment. Each reference in the Agreement to the “date of the
Agreement” or similar references (such as “to the date hereof”) shall refer to March 7, 2015. 
 4.2 Related
Agreement. The parties hereto acknowledge and agree that (i) Baudax and APIL are also parties to that certain Asset Transfer and License Agreement, dated as of April 10, 2015, as amended on December 23, 2015 and December 20,
2018 and as partially assigned to Baudax pursuant to the Partial Assignment, Assumption and Bifurcation Agreement, dated as of November 20, 2019 (the “Related Agreement”), pursuant to which Baudax is obligated to pay APIL the Earn-Out Consideration set forth in Exhibit D to the Related Agreement, which payment obligation is replicated in Exhibit E to the Agreement, (ii) the Related Agreement is being further amended
concurrently with this Amendment such that the amendments to the Earn-Out Consideration set forth in this Amendment are mirrored in Exhibit D to the Related Agreement and (iii) the Earn-Out Consideration (set forth in Exhibit E to the Agreement, as amended by this Amendment, and Exhibit D to the Related Agreement, as amended) is to be paid by Baudax to APIL only once. 

4.3 Miscellaneous Provisions. The provisions of Article XI of the Agreement shall apply mutatis mutandis to this Amendment and
to the Agreement as modified by this Amendment. 
 [Signature Page Follows] 

  
 -3- 

 IN WITNESS WHEREOF, this Amendment has been signed by or on behalf of each of the parties
set forth below as of the date first above written. 
  

			
	ALKERMES PHARMA IRELAND LIMITED
		
	By:	 	/s/ Richie Paul
		 	Name: Richie Paul
		 	Title: Director
	
	DARAVITA LIMITED
		
	By:	 	/s/ Richie Paul
		 	Name: Richie Paul
		 	Title: Director
	
	ALKERMES US HOLDINGS, INC.
		
	By:	 	/s/ James Frates
		 	Name: James Frates
		 	Title: Director
	
	BAUDAX BIO, INC.
		
	By:	 	/s/ Ryan D. Lake
		 	Name: Ryan D. Lake
		 	Title: Chief Financial Officer

  
 [Signature Page to
Third Amendment to Purchase and Sale Agreement]EX-10.2

 Exhibit 10.2 

THIRD AMENDMENT TO ASSET TRANSFER AND LICENSE AGREEMENT 

This Third Amendment to Asset Transfer and License Agreement (this “Third Amendment”), dated August 17, 2020, entered
into by and between Alkermes Pharma Ireland Limited, a private company limited by shares and incorporated in Ireland (“APIL”), Baudax Bio, Inc., a Pennsylvania corporation (“Baudax”) and Recro Gainesville LLC, a
Massachusetts limited liability company (as successor to Recro Technology LLC f/k/a DV Technology LLC) (“Recro Gainesville” and together with Baudax and APIL, the “Parties”), amends that certain Asset Transfer and
License Agreement, dated as of April 10, 2015 and amended on each of December 23, 2015 and December 20, 2018, by and among APIL and Recro Gainesville (and partially assigned to Baudax as set forth below) (as so amended and partially
assigned, the “Agreement”). 
 RECITALS: 

WHEREAS, the Agreement was originally entered into between APIL and DV Technology LLC; 

WHEREAS, DV Technology LLC was subsequently merged with and into Recro Gainesville, and Recro Gainesville assumed the rights and obligations
of DV Technology LLC as “Purchaser” under the Agreement; 
 WHEREAS, pursuant to that certain Partial Assignment, Assumption and
Bifurcation Agreement by and among Recro Gainesville, Baudax and APIL (the “Bifurcation Agreement”), certain of Recro Gainesville’s rights and obligations under the Agreement were assigned to, and assumed by, Baudax, including
without limitation Recro Gainesville’s obligations as “Purchaser” in respect of the Earn-Out Products, as set forth in Exhibit D to the Agreement; 

WHEREAS, pursuant to the Agreement and the Bifurcation Agreement, Baudax is obligated to pay to APIL the
Earn-Out Consideration set forth in Exhibit D to the Agreement, which Earn-Out Consideration was initially set forth in Exhibit E to that certain Purchase and
Sale Agreement, dated as of March 7, 2015, and amended on each of December 8, 2016 and December 20, 2018, by and among Recro Gainesville (as successor to Recro Pharma LLC), Recro Pharma, Inc., APIL, Alkermes US Holdings, Inc. (as
successor to Eagle Holdings USA, Inc.) and Daravita Limited (the “P&S Agreement”); 
 WHEREAS, pursuant to
Section 11 of the Agreement, APIL, Baudax and Recro Gainesville now desire to amend Exhibit D to the Agreement as set forth herein; and 

WHEREAS, concurrently with this Third Amendment, the P&S Agreement is being amended to modify Exhibit E thereto in a manner that mirrors
the amendments to Exhibit D of the Agreement reflected herein. 

 NOW, THEREFORE, in consideration of the respective premises, mutual covenants and agreements
of the Parties, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: 

ARTICLE I 
 DEFINITIONS 

1.1 Defined Terms. Capitalized terms used but not defined in this Third Amendment shall have the meanings ascribed to them in the
Agreement. 
 ARTICLE II 

AMENDMENT 
 2.1 Exhibit D.
Section 2.1(a) of Exhibit D to the Agreement is hereby deleted in its entirety and replaced with the following: 
 “(a)
Development Milestone Earn-Out Consideration. 
 (i) The following amounts
(“Development Milestone Earn-Out Consideration”) shall be payable in accordance with Section 5 of the Agreement and this Exhibit D upon achievement of the following events
(“Development Milestones”) by Purchaser and its Affiliates, licensees and sublicensees, and shall be non-refundable and non-creditable and not subject
to deduction or set-off: 
 (A) Within thirty (30) calendar days following
December 20, 2018, Purchaser shall pay to APIL Five Million U.S. Dollars (US$5,000,000.00) and within thirty (30) calendar days following March 24, 2019, Purchaser shall pay to APIL Five Million U.S. Dollars (US$5,000,000.00); and
(B) the following amounts: 
  

					
	 Development Milestone
	  	Amount of
Development
Milestone Earn-Out
Consideration (U.S.
Dollars)	 
	 Approval of an NDA for the first Earn-Out Product (the
“First Approval”)
	  	$	5,000,000.00	 
	 First anniversary of the First Approval
	  	$	6,429,000.00	 
	 Second anniversary of the First Approval
	  	$	6,429,000.00	 
	 Third anniversary of the First Approval
	  	$	6,429,000.00	 
	 Fourth anniversary of the First Approval
	  	$	6,429,000.00	 
	 Fifth anniversary of the First Approval
	  	$	6,429,000.00	 
	 Sixth anniversary of the First Approval
	  	$	6,429,000.00	 
	 Seventh anniversary of the First Approval
	  	$	6,429,000.00	 

 (ii) Purchaser shall notify and pay to APIL (A) with respect to the Development Milestone Earn-Out Consideration payable upon the First Approval, (x) Two Million Five Hundred Thousand U.S. Dollars (US$2,500,000.00) of such payment amount on or prior to August 18, 2020, (y) One Million Sixty
Thousand U.S. Dollars (US$1,060,000.00) of such payment amount on or prior to December 20, 

  
 2 

 
2020 and (z) One Million Four Hundred Forty Thousand U.S. Dollars (US$1,440,000.00) of such payment amount on or prior to June 20, 2021 and (B) each Development Milestone Earn-Out Consideration payment other than the First Approval payment within thirty (30) calendar days after the occurrence of the corresponding Development Milestone. Each payment made pursuant to
Section 2.1(a) of this Exhibit D shall be made by wire transfer of immediately available funds to such account or accounts as are designated in writing by APIL.” 

ARTICLE III 
 GENERAL 

3.1 Bifurcation Agreement. The Parties acknowledge that, pursuant to the Bifurcation Agreement, the Assigned Rights and Obligations (as
defined in the Bifurcation Agreement) were irrevocably assigned, conveyed and transferred by Recro Gainesville to Baudax. The Parties further acknowledge and agree that any future amendments, waivers and modifications to the Agreement with respect
to the Assigned Rights and Obligations may be made by written agreement of Baudax and APIL only and do not require the agreement, consent, waiver or signature of Recro Gainesville. 

3.2 Integration; Modification. Except as amended by this Third Amendment, the Agreement shall remain in full force and effect in
accordance with its terms. In the event of a conflict between the provisions of the Agreement and those of this Third Amendment, this Third Amendment shall control. This Third Amendment, together with the Agreement, represent the entire agreement
between the Parties regarding the subject matter hereof. No amendment or modification of the terms and conditions of this Third Amendment shall be binding on any party hereto unless reduced to a writing referencing this Third Amendment and signed by
an authorized representative of the party(ies) to be bound. 
 3.3 Governing Law. This Third Amendment shall be governed by and
construed in accordance with the laws of the State of Delaware, without giving effect to any principles, statutory provisions or other rules of choice of law that would require the application of the laws of a different state or country. 

3.4 Counterparts. This Third Amendment may be executed in counterparts, each of which shall be deemed to be an original, and all of
which taken together shall constitute one agreement binding on the Parties. Signatures provided by facsimile transmission or in PDF or similar digital image format sent by electronic mail shall be deemed to be original signatures. 

[SIGNATURE PAGE FOLLOWS] 

  
 3 

 IN WITNESS WHEREOF, each of the Parties has caused its duly authorized representative to
execute this Third Amendment as of the date first set forth above. 
  

			
	ALKERMES PHARMA IRELAND LIMITED
		
	By	 	/s/ Richie Paul
	Name: Richie Paul
	Title: Director
	
	BAUDAX BIO, INC.
		
	By	 	/s/ Ryan D. Lake
	Name: Ryan D. Lake
	Title: Chief Financial Officer
	
	RECRO GAINESVILLE LLC
		
	By	 	/s/ Gerri Henwood
	Name: Gerri Henwood
	Title: Chief Executive Officer and Director

  
 [Signature Page to
Third Amendment to Asset Transfer and License Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}]]